Opiant Pharmaceuticals Announces Contract Extension of Second Tranche of Approximately $2.4 Million from Biomedical Advanced Research and Development Authority for Development of OPNT003, ...
Opiant Pharmaceuticals, Inc. (OPNT)
Last opiant pharmaceuticals, inc. earnings: 3/4 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.opiant.com/investor-overview
Company Research
Source: GlobeNewswire
SANTA MONICA, Calif., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it has been awarded the second tranche of approximately $2.4 million from the total contract award of up to a maximum of approximately $4.6 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Health and Human Services Office of the Assistant Secretary for Preparedness and Response, to accelerate Opiant’s development of OPNT003, nasal nalmefene, a potent, long-acting opioid antagonist currently in development for the treatment of opioid overdose. Opiant intends to pursue a 505(b)(2) development path for OPNT003 and anticipates the potential to submit a New Drug Application for the drug and intranasal delivery device combination in the fourth quarter 2020. “The award of this second tranche aligns with the progress
Show less
Read more
Impact Snapshot
Event Time:
OPNT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OPNT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OPNT alerts
High impacting Opiant Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
OPNT
News
- Opiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCGlobeNewswire
- Opiant Pharmaceuticals Announces Expiration of Hart-Scott-Rodino Waiting Period for Proposed Acquisition by Indivior PLCGlobeNewswire
- Horizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals [Seeking Alpha]Seeking Alpha
- Opiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseGlobeNewswire
- Opiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown In [Seeking Alpha]Seeking Alpha
OPNT
Earnings
- 8/11/22 - Miss
OPNT
Sec Filings
- 3/3/23 - Form 4
- 3/3/23 - Form 4
- 3/3/23 - Form 4
- OPNT's page on the SEC website